Savara (SVRA) Long-Term Debt Repayments (2017 - 2025)

Savara (SVRA) posted quarterly Long-Term Debt Repayments of -$1000.0 for Q3 2025, down 100.0% quarter-over-quarter from $27.2 million in Q1 2025.

Savara (SVRA) Long-Term Debt Repayments (2017 - 2025) Analysis & Trends

Savara (SVRA) has reported Long-Term Debt Repayments for 2 consecutive years, with -$1000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Long-Term Debt Repayments changed N/A year-over-year to -$1000.0; the TTM figure through Dec 2025 stood at $27.2 million (changed N/A YoY), while the FY2025 annual figure was $27.2 million, changed N/A from the prior year.
Long-Term Debt Repayments slipped to -$1000.0 in Q3 2025 per SVRA's latest filing, from $27.2 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $27.2 million in Q1 2025 and bottomed at -$1000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	17.05 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data